← Leaderboards
David Robert Clemmons
University Of North Carolina Chapel Hill
$15,091,383
Attributed
$16,281,313
Total exposure
15
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–15$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$23,672,975 · 16
By mechanism
P01$9,513,731 · 3
R01$8,202,413 · 4
R37$3,698,096 · 1
M01$2,048,475 · 7
R41$210,260 · 1
Top collaborators
- Clifford J Rosen6 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Julie Lund Sharpless$932,166
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchDrug Screening /EvaluationPhosphorylationInsulinlike Growth FactorSomatotropinIntegrinsExtracellular MatrixRecombinant ProteinsHuman Therapy EvaluationLigandsBinding ProteinsSignal TransductionMediatingEndocrine Disorder ChemotherapyReceptorAtherosclerosisAcromegalyInsulin-Like Growth Factor IPathway Interactions1-Phosphatidylinositol 3-KinaseMolecularProtein BindingSwine
Grant awards (71)
Determination of the Mechanisms by which IGFBP-2 Stimulates Bone Remodeling$459,797
R01 · FY2015 · AR
Determination of the Mechanisms by which IGFBP-2 Stimulates Bone Remodeling$100,000
R01 · FY2015 · AR
Determination of the Mechanisms by which IGFBP-2 Stimulates Bone Remodeling$450,644
R01 · FY2014 · AR
Determination of the Mechanisms by which IGFBP-2 Stimulates Bone Remodeling$436,891
R01 · FY2013 · AR
Role of Integrins/ECM in Controlling IGF-I Actions$369,497
R37 · FY2013 · AG · contact PI
Determination of the Mechanisms by which IGFBP-2 Stimulates Bone Remodeling$459,928
R01 · FY2012 · AR
Role of Integrins/ECM in Controlling IGF-I Actions$391,001
R37 · FY2012 · AG · contact PI
Determination of the mechanisms by which IGFBP-2 stimulates bone remodeling$472,601
R01 · FY2011 · AR
Role of Integrins/ECM in Controlling IGF-I Actions$391,001
R37 · FY2011 · AG · contact PI
Role of Integrins/ECM in Controlling IGF-I Actions$406,784
R37 · FY2010 · AG · contact PI
Role of Integrins/ECM in Controlling IGF-I Actions$410,661
R37 · FY2009 · AG · contact PI
Chaperones, ROS systems, & IGF-1:Roles in vascular aging$1,510,079
P01 · FY2008 · AG · contact PI
IGF-1 SIGNALING AND VASCULAR AGING$422,275
P01 · FY2008 · AG · contact PI
Role of Integrins/ECM in Controlling IGF-I Actions$331,024
R37 · FY2008 · AG · contact PI
CLINICAL TRIAL: METFORMIN ON CHANGES IN AMPKINASE ACTIVITY IN PERIPHERAL BLOOD$5,280
M01 · FY2008 · RR · contact PI
ATORVASTATIN ON PLASMA CHOLINE CONCENTRATION IN SUBJECTS WITH AND WITHOUT THE ME$1,913
M01 · FY2008 · RR · contact PI
Chaperones, ROS systems, & IGF-1:Roles in vascular aging$1,496,023
P01 · FY2007 · AG · contact PI
IGF-1 SIGNALING AND VASCULAR AGING$418,351
P01 · FY2007 · AG · contact PI
Role of Integrins/ECM in Controlling IGF-I Actions$337,780
R37 · FY2007 · AG · contact PI
MECHANISMS BY WHICH IGF-I STIMULATES SMOOTH MUSCLE CELLS$51,100
R01 · FY2007 · HL · contact PI
IGF-1 POLYMORPHISM OF DIABETIC AND PREDIABETIC SUBJECTS AND ASSOCIATED INSULIN$6,565
M01 · FY2007 · RR · contact PI
Chaperones, ROS systems, & IGF-1:Roles in vascular aging$1,495,823
P01 · FY2006 · AG · contact PI
MECHANISMS BY WHICH IGF-I STIMULATES SMOOTH MUSCLE CELLS$416,134
R01 · FY2006 · HL · contact PI
IGF-1 SIGNALING AND VASCULAR AGING$390,696
P01 · FY2006 · AG · contact PI
Role of Integrins/ECM in Controlling IGF-I Actions$347,868
R37 · FY2006 · AG · contact PI
Development of a Novel Method for Inhibiting Atherosclerosis in Diabetes$210,260
R41 · FY2006 · HL · contact PI
MECHANISMS BY WHICH IGF-I STIMULATES SMOOTH MUSCLE CELLS$113,150
R01 · FY2006 · HL · contact PI
IGF-1 POLYMORPHISM OF DIABETIC AND PREDIABETIC SUBJECTS AND ASSOCIATED INSULIN$4,956
M01 · FY2006 · RR · contact PI
Chaperones, ROS systems, &IGF-1:Roles in vascular aging$1,471,486
P01 · FY2005 · AG
ARTHEROSCLEROSIS IN INSULIN-RESISTANT, HYPERLIPIDEMIC P*$464,190
R01 · FY2005 · HL
MECHANISMS BY WHICH IGF-I STIMULATES SMOOTH MUSCLE CELLS$419,082
R01 · FY2005 · HL
IGF-1 SIGNALING AND VASCULAR AGING$379,317
P01 · FY2005 · AG
Role of Integrins/ECM in Controlling IGF-I Actions$356,240
R37 · FY2005 · AG
Chaperones, ROS systems, &IGF-1:Roles in vascular aging$1,418,251
P01 · FY2004 · AG
ARTHEROSCLEROSIS IN INSULIN-RESISTANT, HYPERLIPIDEMIC P*$453,849
R01 · FY2004 · HL
MECHANISMS BY WHICH IGF-I STIMULATES SMOOTH MUSCLE CELLS$407,388
R01 · FY2004 · HL
IGF-1 SIGNALING AND VASCULAR AGING$384,470
P01 · FY2004 · AG
Role of Integrins/ECM in Controlling IGF-I Actions$356,240
R37 · FY2004 · AG
ADMINISTRATIVE CORE$126,960
P01 · FY2004 · AG
IGF-1/IGFBP-3 on Lipoprotein Subfractions and Insulin Sensitivity in Patients$849
M01 · FY2004 · RR
IGF-1 polymorphism of diabetic and prediabetic subjects and associated insulin$283
M01 · FY2004 · RR
ARTHEROSCLEROSIS IN INSULIN-RESISTANT, HYPERLIPIDEMIC P*$447,247
R01 · FY2003 · HL
MECHANISMS BY WHICH IGF-I STIMULATES SMOOTH MUSCLE CELLS$398,910
R01 · FY2003 · HL
ARTHEROSCLEROSIS IN INSULIN-RESISTANT, HYPERLIPIDEMIC P*$529,893
R01 · FY2002 · HL
MECHANISMS BY WHICH IGF-I STIMULATES SMOOTH MUSCLE CELLS$388,057
R01 · FY2002 · HL
IGFBP5 AND INTEGRINS AND CONTROLLING IGF1 ACTIONS$363,513
R01 · FY2002 · AG
COMBINATION OF RHU INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 3$190,747
M01 · FY2002 · RR
B2036 PEG IN TREATMENT OF ACROMEGALY$190,747
M01 · FY2002 · RR
STUDY OF B2036-PED IN TREATMENT OF ACROMEGALY$190,747
M01 · FY2002 · RR
ATHEROSCLEROSIS IN INSULIN-RESISTANT, HYPERLIPIDEMIC PTS$373,482
R01 · FY2001 · HL
IGFBP5 AND INTEGRINS AND CONTROLLING IGF1 ACTIONS$337,276
R01 · FY2001 · AG
STUDY OF B2036-PED IN TREATMENT OF ACROMEGALY$294,555
M01 · FY2001 · RR
B2036 PEG IN TREATMENT OF ACROMEGALY$294,555
M01 · FY2001 · RR
COMBINATION OF RHU INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 3$294,555
M01 · FY2001 · RR
STUDY OF B2036-PED IN TREATMENT OF ACROMEGALY$190,747
M01 · FY2001 · RR
B2036 PEG IN TREATMENT OF ACROMEGALY$190,747
M01 · FY2001 · RR
COMBINATION OF RHU INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 3$190,747
M01 · FY2001 · RR
IGFBP5 AND INTEGRINS AND CONTROLLING IGF1 ACTIONS$332,149
R01 · FY2000 · AG
MECHANISMS BY WHICH IGF I STIMULATES SMOOTH MUSCLE CELLS$327,132
R01 · FY2000 · HL
B2036 PEG IN TREATMENT OF ACROMEGALY$241
M01 · FY2000 · RR
COMBINATION OF RHU INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 3$241
M01 · FY2000 · RR
STUDY OF B2036-PED IN TREATMENT OF ACROMEGALY$0
M01 · FY2000 · RR
B2036 PEG IN TREATMENT OF ACROMEGALY$0
M01 · FY2000 · RR
B2036 PEG IN TREATMENT OF ACROMEGALY$0
M01 · FY2000 · RR
B2036 PEG IN TREATMENT OF ACROMEGALY$0
M01 · FY2000 · RR
COMBINATION OF RHU INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 3$0
M01 · FY2000 · RR
COMBINATION OF RHU INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 3$0
M01 · FY2000 · RR
COMBINATION OF RHU INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 3$0
M01 · FY2000 · RR
STUDY OF B2036-PED IN TREATMENT OF ACROMEGALY$0
M01 · FY2000 · RR
STUDY OF B2036-PED IN TREATMENT OF ACROMEGALY$0
M01 · FY2000 · RR
STUDY OF B2036-PED IN TREATMENT OF ACROMEGALY$0
M01 · FY2000 · RR